Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF study.
Identifieur interne : 002344 ( Main/Exploration ); précédent : 002343; suivant : 002345Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF study.
Auteurs : Ken Lee Chin [Australie] ; Timothy J. Collier [Royaume-Uni] ; Bertram Pitt [États-Unis] ; John J V. Mcmurray [Royaume-Uni] ; Karl Swedberg [Suède] ; Dirk J. Van Veldhuisen [Pays-Bas] ; Stuart J. Pocock [Royaume-Uni] ; John Vincent [États-Unis] ; Eva Turgonyi [États-Unis] ; Faiez Zannad [France] ; Henry Krum [Australie]Source :
- European journal of heart failure [ 1879-0844 ] ; 2016.
Descripteurs français
- KwdFr :
- Acide acétylsalicylique (usage thérapeutique), Antagonistes des récepteurs des minéralocorticoïdes (usage thérapeutique), Antiagrégants plaquettaires (usage thérapeutique), Débit systolique, Défaillance cardiaque systolique (physiopathologie), Défaillance cardiaque systolique (traitement médicamenteux), Femelle, Humains, Interactions médicamenteuses, Maladie chronique, Modèles de hasards proportionnels, Mâle, Potassium (sang), Pression sanguine, Spironolactone (analogues et dérivés), Spironolactone (usage thérapeutique), Sujet âgé, Taux de filtration glomérulaire.
- MESH :
- analogues et dérivés : Spironolactone.
- physiopathologie : Défaillance cardiaque systolique.
- sang : Potassium.
- traitement médicamenteux : Défaillance cardiaque systolique.
- usage thérapeutique : Acide acétylsalicylique, Antagonistes des récepteurs des minéralocorticoïdes, Antiagrégants plaquettaires, Spironolactone.
- Débit systolique, Femelle, Humains, Interactions médicamenteuses, Maladie chronique, Modèles de hasards proportionnels, Mâle, Pression sanguine, Sujet âgé, Taux de filtration glomérulaire.
English descriptors
- KwdEn :
- Aged, Aspirin (therapeutic use), Blood Pressure, Chronic Disease, Drug Interactions, Female, Glomerular Filtration Rate, Heart Failure, Systolic (drug therapy), Heart Failure, Systolic (physiopathology), Humans, Male, Mineralocorticoid Receptor Antagonists (therapeutic use), Platelet Aggregation Inhibitors (therapeutic use), Potassium (blood), Proportional Hazards Models, Spironolactone (analogs & derivatives), Spironolactone (therapeutic use), Stroke Volume.
- MESH :
- chemical , analogs & derivatives : Spironolactone.
- chemical , blood : Potassium.
- chemical , therapeutic use : Aspirin, Mineralocorticoid Receptor Antagonists, Platelet Aggregation Inhibitors, Spironolactone.
- drug therapy : Heart Failure, Systolic.
- physiopathology : Heart Failure, Systolic.
- Aged, Blood Pressure, Chronic Disease, Drug Interactions, Female, Glomerular Filtration Rate, Humans, Male, Proportional Hazards Models, Stroke Volume.
Abstract
It is not known whether concomitant use of aspirin might attenuate the beneficial effects of mineralocorticoid receptor antagonists (MRAs). The purpose of this subgroup analysis was to explore the interaction between baseline aspirin treatment and the effect of eplerenone on the primary efficacy outcomes (composite of hospitalization for heart failure or cardiovascular mortality), its components, and safety markers [estimated glomerular filtration rate (eGFR), systolic blood pressure (SBP), and serum potassium >5.5 mmol/L] in the Eplerenone in Mild Patients Hospitalization and SurvIval Study in Heart Failure trial (EMPHASIS-HF).
DOI: 10.1002/ejhf.485
PubMed: 26833642
Affiliations:
- Australie, France, Pays-Bas, Royaume-Uni, Suède, États-Unis
- Angleterre, Grand Est, Grand Londres, Groningue (province), Lorraine (région), Michigan, Victoria (État), Écosse, État de New York
- Glasgow, Groningue, Groningue (ville), Londres, Melbourne, Nancy
- Université de Glasgow, Université de Groningue
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001A02
- to stream PubMed, to step Curation: 001978
- to stream PubMed, to step Checkpoint: 001978
- to stream Ncbi, to step Merge: 003084
- to stream Ncbi, to step Curation: 003084
- to stream Ncbi, to step Checkpoint: 003084
- to stream Main, to step Merge: 002343
- to stream Main, to step Curation: 002344
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF study.</title><author><name sortKey="Chin, Ken Lee" sort="Chin, Ken Lee" uniqKey="Chin K" first="Ken Lee" last="Chin">Ken Lee Chin</name><affiliation wicri:level="3"><nlm:affiliation>Centre of Cardiovascular Research & Education in Therapeutics, Department of Epidemiology & Preventive Medicine, Monash University, Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Centre of Cardiovascular Research & Education in Therapeutics, Department of Epidemiology & Preventive Medicine, Monash University, Melbourne</wicri:regionArea><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Collier, Timothy J" sort="Collier, Timothy J" uniqKey="Collier T" first="Timothy J" last="Collier">Timothy J. Collier</name><affiliation wicri:level="3"><nlm:affiliation>London School of Hygiene and Tropical Medicine, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>London School of Hygiene and Tropical Medicine, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Pitt, Bertram" sort="Pitt, Bertram" uniqKey="Pitt B" first="Bertram" last="Pitt">Bertram Pitt</name><affiliation wicri:level="2"><nlm:affiliation>University of Michigan School of Medicine, Ann Arbor, MI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Michigan School of Medicine, Ann Arbor, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Mcmurray, John J V" sort="Mcmurray, John J V" uniqKey="Mcmurray J" first="John J V" last="Mcmurray">John J V. Mcmurray</name><affiliation wicri:level="4"><nlm:affiliation>British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow</wicri:regionArea><orgName type="university">Université de Glasgow</orgName><placeName><settlement type="city">Glasgow</settlement><region type="country">Écosse</region></placeName></affiliation></author><author><name sortKey="Swedberg, Karl" sort="Swedberg, Karl" uniqKey="Swedberg K" first="Karl" last="Swedberg">Karl Swedberg</name><affiliation wicri:level="1"><nlm:affiliation>Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg</wicri:regionArea><wicri:noRegion>Gothenburg</wicri:noRegion></affiliation></author><author><name sortKey="Van Veldhuisen, Dirk J" sort="Van Veldhuisen, Dirk J" uniqKey="Van Veldhuisen D" first="Dirk J" last="Van Veldhuisen">Dirk J. Van Veldhuisen</name><affiliation wicri:level="4"><nlm:affiliation>University of Groningen, Groningen, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>University of Groningen, Groningen</wicri:regionArea><placeName><settlement type="city">Groningue</settlement><region nuts="2" type="province">Groningue (province)</region><settlement type="city">Groningue (ville)</settlement></placeName><orgName type="university">Université de Groningue</orgName></affiliation></author><author><name sortKey="Pocock, Stuart J" sort="Pocock, Stuart J" uniqKey="Pocock S" first="Stuart J" last="Pocock">Stuart J. Pocock</name><affiliation wicri:level="3"><nlm:affiliation>London School of Hygiene and Tropical Medicine, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>London School of Hygiene and Tropical Medicine, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Vincent, John" sort="Vincent, John" uniqKey="Vincent J" first="John" last="Vincent">John Vincent</name><affiliation wicri:level="2"><nlm:affiliation>Pfizer, New York, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pfizer, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Turgonyi, Eva" sort="Turgonyi, Eva" uniqKey="Turgonyi E" first="Eva" last="Turgonyi">Eva Turgonyi</name><affiliation wicri:level="2"><nlm:affiliation>Pfizer, New York, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pfizer, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Zannad, Faiez" sort="Zannad, Faiez" uniqKey="Zannad F" first="Faiez" last="Zannad">Faiez Zannad</name><affiliation wicri:level="3"><nlm:affiliation>CHU and University Henri Poincaré, Nancy, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CHU and University Henri Poincaré, Nancy</wicri:regionArea><placeName><region type="region">Grand Est</region><region type="old region">Lorraine (région)</region><settlement type="city">Nancy</settlement></placeName></affiliation></author><author><name sortKey="Krum, Henry" sort="Krum, Henry" uniqKey="Krum H" first="Henry" last="Krum">Henry Krum</name><affiliation wicri:level="3"><nlm:affiliation>Centre of Cardiovascular Research & Education in Therapeutics, Department of Epidemiology & Preventive Medicine, Monash University, Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Centre of Cardiovascular Research & Education in Therapeutics, Department of Epidemiology & Preventive Medicine, Monash University, Melbourne</wicri:regionArea><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26833642</idno><idno type="pmid">26833642</idno><idno type="doi">10.1002/ejhf.485</idno><idno type="wicri:Area/PubMed/Corpus">001A02</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001A02</idno><idno type="wicri:Area/PubMed/Curation">001978</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001978</idno><idno type="wicri:Area/PubMed/Checkpoint">001978</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001978</idno><idno type="wicri:Area/Ncbi/Merge">003084</idno><idno type="wicri:Area/Ncbi/Curation">003084</idno><idno type="wicri:Area/Ncbi/Checkpoint">003084</idno><idno type="wicri:Area/Main/Merge">002343</idno><idno type="wicri:Area/Main/Curation">002344</idno><idno type="wicri:Area/Main/Exploration">002344</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF study.</title><author><name sortKey="Chin, Ken Lee" sort="Chin, Ken Lee" uniqKey="Chin K" first="Ken Lee" last="Chin">Ken Lee Chin</name><affiliation wicri:level="3"><nlm:affiliation>Centre of Cardiovascular Research & Education in Therapeutics, Department of Epidemiology & Preventive Medicine, Monash University, Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Centre of Cardiovascular Research & Education in Therapeutics, Department of Epidemiology & Preventive Medicine, Monash University, Melbourne</wicri:regionArea><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Collier, Timothy J" sort="Collier, Timothy J" uniqKey="Collier T" first="Timothy J" last="Collier">Timothy J. Collier</name><affiliation wicri:level="3"><nlm:affiliation>London School of Hygiene and Tropical Medicine, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>London School of Hygiene and Tropical Medicine, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Pitt, Bertram" sort="Pitt, Bertram" uniqKey="Pitt B" first="Bertram" last="Pitt">Bertram Pitt</name><affiliation wicri:level="2"><nlm:affiliation>University of Michigan School of Medicine, Ann Arbor, MI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Michigan School of Medicine, Ann Arbor, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Mcmurray, John J V" sort="Mcmurray, John J V" uniqKey="Mcmurray J" first="John J V" last="Mcmurray">John J V. Mcmurray</name><affiliation wicri:level="4"><nlm:affiliation>British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow</wicri:regionArea><orgName type="university">Université de Glasgow</orgName><placeName><settlement type="city">Glasgow</settlement><region type="country">Écosse</region></placeName></affiliation></author><author><name sortKey="Swedberg, Karl" sort="Swedberg, Karl" uniqKey="Swedberg K" first="Karl" last="Swedberg">Karl Swedberg</name><affiliation wicri:level="1"><nlm:affiliation>Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg</wicri:regionArea><wicri:noRegion>Gothenburg</wicri:noRegion></affiliation></author><author><name sortKey="Van Veldhuisen, Dirk J" sort="Van Veldhuisen, Dirk J" uniqKey="Van Veldhuisen D" first="Dirk J" last="Van Veldhuisen">Dirk J. Van Veldhuisen</name><affiliation wicri:level="4"><nlm:affiliation>University of Groningen, Groningen, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>University of Groningen, Groningen</wicri:regionArea><placeName><settlement type="city">Groningue</settlement><region nuts="2" type="province">Groningue (province)</region><settlement type="city">Groningue (ville)</settlement></placeName><orgName type="university">Université de Groningue</orgName></affiliation></author><author><name sortKey="Pocock, Stuart J" sort="Pocock, Stuart J" uniqKey="Pocock S" first="Stuart J" last="Pocock">Stuart J. Pocock</name><affiliation wicri:level="3"><nlm:affiliation>London School of Hygiene and Tropical Medicine, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>London School of Hygiene and Tropical Medicine, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Vincent, John" sort="Vincent, John" uniqKey="Vincent J" first="John" last="Vincent">John Vincent</name><affiliation wicri:level="2"><nlm:affiliation>Pfizer, New York, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pfizer, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Turgonyi, Eva" sort="Turgonyi, Eva" uniqKey="Turgonyi E" first="Eva" last="Turgonyi">Eva Turgonyi</name><affiliation wicri:level="2"><nlm:affiliation>Pfizer, New York, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pfizer, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Zannad, Faiez" sort="Zannad, Faiez" uniqKey="Zannad F" first="Faiez" last="Zannad">Faiez Zannad</name><affiliation wicri:level="3"><nlm:affiliation>CHU and University Henri Poincaré, Nancy, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CHU and University Henri Poincaré, Nancy</wicri:regionArea><placeName><region type="region">Grand Est</region><region type="old region">Lorraine (région)</region><settlement type="city">Nancy</settlement></placeName></affiliation></author><author><name sortKey="Krum, Henry" sort="Krum, Henry" uniqKey="Krum H" first="Henry" last="Krum">Henry Krum</name><affiliation wicri:level="3"><nlm:affiliation>Centre of Cardiovascular Research & Education in Therapeutics, Department of Epidemiology & Preventive Medicine, Monash University, Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Centre of Cardiovascular Research & Education in Therapeutics, Department of Epidemiology & Preventive Medicine, Monash University, Melbourne</wicri:regionArea><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author></analytic><series><title level="j">European journal of heart failure</title><idno type="eISSN">1879-0844</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Aspirin (therapeutic use)</term><term>Blood Pressure</term><term>Chronic Disease</term><term>Drug Interactions</term><term>Female</term><term>Glomerular Filtration Rate</term><term>Heart Failure, Systolic (drug therapy)</term><term>Heart Failure, Systolic (physiopathology)</term><term>Humans</term><term>Male</term><term>Mineralocorticoid Receptor Antagonists (therapeutic use)</term><term>Platelet Aggregation Inhibitors (therapeutic use)</term><term>Potassium (blood)</term><term>Proportional Hazards Models</term><term>Spironolactone (analogs & derivatives)</term><term>Spironolactone (therapeutic use)</term><term>Stroke Volume</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Acide acétylsalicylique (usage thérapeutique)</term><term>Antagonistes des récepteurs des minéralocorticoïdes (usage thérapeutique)</term><term>Antiagrégants plaquettaires (usage thérapeutique)</term><term>Débit systolique</term><term>Défaillance cardiaque systolique (physiopathologie)</term><term>Défaillance cardiaque systolique (traitement médicamenteux)</term><term>Femelle</term><term>Humains</term><term>Interactions médicamenteuses</term><term>Maladie chronique</term><term>Modèles de hasards proportionnels</term><term>Mâle</term><term>Potassium (sang)</term><term>Pression sanguine</term><term>Spironolactone (analogues et dérivés)</term><term>Spironolactone (usage thérapeutique)</term><term>Sujet âgé</term><term>Taux de filtration glomérulaire</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Spironolactone</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Potassium</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Aspirin</term><term>Mineralocorticoid Receptor Antagonists</term><term>Platelet Aggregation Inhibitors</term><term>Spironolactone</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Spironolactone</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Heart Failure, Systolic</term></keywords><keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr"><term>Défaillance cardiaque systolique</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Heart Failure, Systolic</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Potassium</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Défaillance cardiaque systolique</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Acide acétylsalicylique</term><term>Antagonistes des récepteurs des minéralocorticoïdes</term><term>Antiagrégants plaquettaires</term><term>Spironolactone</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Blood Pressure</term><term>Chronic Disease</term><term>Drug Interactions</term><term>Female</term><term>Glomerular Filtration Rate</term><term>Humans</term><term>Male</term><term>Proportional Hazards Models</term><term>Stroke Volume</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Débit systolique</term><term>Femelle</term><term>Humains</term><term>Interactions médicamenteuses</term><term>Maladie chronique</term><term>Modèles de hasards proportionnels</term><term>Mâle</term><term>Pression sanguine</term><term>Sujet âgé</term><term>Taux de filtration glomérulaire</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">It is not known whether concomitant use of aspirin might attenuate the beneficial effects of mineralocorticoid receptor antagonists (MRAs). The purpose of this subgroup analysis was to explore the interaction between baseline aspirin treatment and the effect of eplerenone on the primary efficacy outcomes (composite of hospitalization for heart failure or cardiovascular mortality), its components, and safety markers [estimated glomerular filtration rate (eGFR), systolic blood pressure (SBP), and serum potassium >5.5 mmol/L] in the Eplerenone in Mild Patients Hospitalization and SurvIval Study in Heart Failure trial (EMPHASIS-HF).</div></front></TEI><affiliations><list><country><li>Australie</li><li>France</li><li>Pays-Bas</li><li>Royaume-Uni</li><li>Suède</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Grand Est</li><li>Grand Londres</li><li>Groningue (province)</li><li>Lorraine (région)</li><li>Michigan</li><li>Victoria (État)</li><li>Écosse</li><li>État de New York</li></region><settlement><li>Glasgow</li><li>Groningue</li><li>Groningue (ville)</li><li>Londres</li><li>Melbourne</li><li>Nancy</li></settlement><orgName><li>Université de Glasgow</li><li>Université de Groningue</li></orgName></list><tree><country name="Australie"><region name="Victoria (État)"><name sortKey="Chin, Ken Lee" sort="Chin, Ken Lee" uniqKey="Chin K" first="Ken Lee" last="Chin">Ken Lee Chin</name></region><name sortKey="Krum, Henry" sort="Krum, Henry" uniqKey="Krum H" first="Henry" last="Krum">Henry Krum</name></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Collier, Timothy J" sort="Collier, Timothy J" uniqKey="Collier T" first="Timothy J" last="Collier">Timothy J. Collier</name></region><name sortKey="Mcmurray, John J V" sort="Mcmurray, John J V" uniqKey="Mcmurray J" first="John J V" last="Mcmurray">John J V. Mcmurray</name><name sortKey="Pocock, Stuart J" sort="Pocock, Stuart J" uniqKey="Pocock S" first="Stuart J" last="Pocock">Stuart J. Pocock</name></country><country name="États-Unis"><region name="Michigan"><name sortKey="Pitt, Bertram" sort="Pitt, Bertram" uniqKey="Pitt B" first="Bertram" last="Pitt">Bertram Pitt</name></region><name sortKey="Turgonyi, Eva" sort="Turgonyi, Eva" uniqKey="Turgonyi E" first="Eva" last="Turgonyi">Eva Turgonyi</name><name sortKey="Vincent, John" sort="Vincent, John" uniqKey="Vincent J" first="John" last="Vincent">John Vincent</name></country><country name="Suède"><noRegion><name sortKey="Swedberg, Karl" sort="Swedberg, Karl" uniqKey="Swedberg K" first="Karl" last="Swedberg">Karl Swedberg</name></noRegion></country><country name="Pays-Bas"><region name="Groningue (province)"><name sortKey="Van Veldhuisen, Dirk J" sort="Van Veldhuisen, Dirk J" uniqKey="Van Veldhuisen D" first="Dirk J" last="Van Veldhuisen">Dirk J. Van Veldhuisen</name></region></country><country name="France"><region name="Grand Est"><name sortKey="Zannad, Faiez" sort="Zannad, Faiez" uniqKey="Zannad F" first="Faiez" last="Zannad">Faiez Zannad</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002344 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002344 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:26833642
|texte= Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26833642" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |